RU2011140869A - Пиперазиновое соединение, ингибирующее простагландин-d-синтазу - Google Patents
Пиперазиновое соединение, ингибирующее простагландин-d-синтазу Download PDFInfo
- Publication number
- RU2011140869A RU2011140869A RU2011140869/04A RU2011140869A RU2011140869A RU 2011140869 A RU2011140869 A RU 2011140869A RU 2011140869/04 A RU2011140869/04 A RU 2011140869/04A RU 2011140869 A RU2011140869 A RU 2011140869A RU 2011140869 A RU2011140869 A RU 2011140869A
- Authority
- RU
- Russia
- Prior art keywords
- carbonyl
- piperazinecarboxamide
- methylpyrrol
- phenyl
- substituents
- Prior art date
Links
- -1 Piperazine Compound Chemical class 0.000 title claims abstract 15
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title claims abstract 9
- 102000048176 Prostaglandin-D synthases Human genes 0.000 title claims 2
- 108030003866 Prostaglandin-D synthases Proteins 0.000 title claims 2
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 4
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 4
- 125000001425 triazolyl group Chemical group 0.000 claims abstract 4
- 150000002431 hydrogen Chemical group 0.000 claims abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 claims abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 claims abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000002207 metabolite Substances 0.000 claims 5
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 5
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 1
- SGEKWCSVGFTSKH-UHFFFAOYSA-N 1-amino-4-phenylpiperidine-4-carboxylic acid Chemical compound NN1CCC(CC1)(C(O)=O)c1ccccc1 SGEKWCSVGFTSKH-UHFFFAOYSA-N 0.000 claims 1
- SHMGBVYQEIXSFM-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[3-[2-(1,2,4-triazol-1-yl)ethyl]pyrrolidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CC(CCN3N=CN=C3)CC2)CC1 SHMGBVYQEIXSFM-UHFFFAOYSA-N 0.000 claims 1
- XYSYJYTWKAIUAF-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-(2-morpholin-4-ylethyl)piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CCN3CCOCC3)CC2)CC1 XYSYJYTWKAIUAF-UHFFFAOYSA-N 0.000 claims 1
- QEPAIZPHKGNYIB-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-(2-morpholin-4-ylethylcarbamoyl)piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CC2)C(=O)NCCN2CCOCC2)CC1 QEPAIZPHKGNYIB-UHFFFAOYSA-N 0.000 claims 1
- YNDOYMIWZOONKU-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-(2-pyrazol-1-ylethyl)piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CCN3N=CC=C3)CC2)CC1 YNDOYMIWZOONKU-UHFFFAOYSA-N 0.000 claims 1
- IXXKCLWHNVBNOT-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-(morpholin-4-ylmethyl)piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CN3CCOCC3)CC2)CC1 IXXKCLWHNVBNOT-UHFFFAOYSA-N 0.000 claims 1
- DYCWDVDJZWQLNX-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-(piperidine-1-carbonyl)piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CC2)C(=O)N2CCCCC2)CC1 DYCWDVDJZWQLNX-UHFFFAOYSA-N 0.000 claims 1
- ABURWQHMGKKILS-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-(pyridin-3-ylmethylcarbamoyl)piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CC2)C(=O)NCC=2C=NC=CC=2)CC1 ABURWQHMGKKILS-UHFFFAOYSA-N 0.000 claims 1
- WLKVELGPPPLJBF-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-[2-(1,2,4-triazol-1-yl)ethyl]piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CCN3N=CN=C3)CC2)CC1 WLKVELGPPPLJBF-UHFFFAOYSA-N 0.000 claims 1
- MJQUKLCVROIMDE-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-[3-(1,2,4-triazol-1-yl)propyl]piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CCCN3N=CN=C3)CC2)CC1 MJQUKLCVROIMDE-UHFFFAOYSA-N 0.000 claims 1
- PCXBSEICUDUWMQ-UHFFFAOYSA-N 4-(1-methylpyrrole-2-carbonyl)-n-[4-[4-[3-(triazol-1-yl)propyl]piperidin-1-yl]phenyl]piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(CCCN3N=NC=C3)CC2)CC1 PCXBSEICUDUWMQ-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- MCIXIOJTXYAIBD-UHFFFAOYSA-N n-[4-(4-hydroxypiperidin-1-yl)phenyl]-4-(1-methylpyrrole-2-carbonyl)piperazine-1-carboxamide Chemical compound CN1C=CC=C1C(=O)N1CCN(C(=O)NC=2C=CC(=CC=2)N2CCC(O)CC2)CC1 MCIXIOJTXYAIBD-UHFFFAOYSA-N 0.000 claims 1
- OAUPRNHAMRWWOG-UHFFFAOYSA-N n-[4-[4-(4-methylpiperazine-1-carbonyl)piperidin-1-yl]phenyl]-4-(1-methylpyrrole-2-carbonyl)piperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1CCN(C=2C=CC(NC(=O)N3CCN(CC3)C(=O)C=3N(C=CC=3)C)=CC=2)CC1 OAUPRNHAMRWWOG-UHFFFAOYSA-N 0.000 claims 1
- XBZATZBFXPOSMS-UHFFFAOYSA-N n-[4-[4-[2-(3,5-dimethyl-1,2,4-triazol-1-yl)ethyl]piperidin-1-yl]phenyl]-4-(1-methylpyrrole-2-carbonyl)piperazine-1-carboxamide Chemical compound N1=C(C)N=C(C)N1CCC1CCN(C=2C=CC(NC(=O)N3CCN(CC3)C(=O)C=3N(C=CC=3)C)=CC=2)CC1 XBZATZBFXPOSMS-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 0 CC(C*1)C(*)CCN1c(cc1)ccc1NC(N(CC1)CCN1C(c1ccc[n]1*)=O)=O Chemical compound CC(C*1)C(*)CCN1c(cc1)ccc1NC(N(CC1)CCN1C(c1ccc[n]1*)=O)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
Abstract
1. Пиперазиновое соединение, представленное формулой (I),где Rпредставляет собой Cалкил;Rпредставляет собой гидрокси, Cалкил, который может содержать один или более заместителей, -(C=O)-N(R)(R) или -(C=O)-OR;Rи Rмогут быть одинаковыми или отличаться, и каждый представляет собой водород или Cалкил, который может содержать один или более заместителей, илиRи R, связанные через атом азота, к которому присоединены Rи R, могут образовывать насыщенную гетероциклическую группу;Rпредставляет собой водород или Cалкил, который может содержать один или более заместителей; иn представляет собой 1 или 2;или его соль.2. Пиперазиновое соединение или его соль в соответствии с п.1, гдеRпредставляет собой метил или этил;Rпредставляет собой гидрокси, Cалкил, который может иметь одну или более насыщенных или ненасыщенных гетероциклических групп в качестве заместителей, -(C=O)-N(R)(R) или -(C=O)-OR;Rи Rмогут быть одинаковыми или отличаться, и каждый представляет собой водород или Cалкил, который может иметь одну или более насыщенных или ненасыщенных гетероциклических групп в качестве заместителей, илиRи R, связанные через атом азота, к которому присоединены Rи R, могут образовать пирролидинил, пиперидинил, пиперазинил и морфолино;Rпредставляет собой водород, метил, этил, трет-бутил или бензил; иn представляет собой 1 или 2.3. Пиперазиновое соединение или его соль в соответствии с п.1, гдеRпредставляет собой метил;Rпредставляет собой Cалкил, который может содержать морфолино, пиразолил или триазолил в качестве заместителей, -(C=O)-N(R)(R) или -(C=O)-OR; и триазолил может содержать один или два заместителя;Rи R, связанные через атом азота, к которому присоединены Rи R, могут образовыва�
Claims (11)
1. Пиперазиновое соединение, представленное формулой (I),
где R1 представляет собой C1-6 алкил;
R2 представляет собой гидрокси, C1-6 алкил, который может содержать один или более заместителей, -(C=O)-N(R3)(R4) или -(C=O)-OR5;
R3 и R4 могут быть одинаковыми или отличаться, и каждый представляет собой водород или C1-6 алкил, который может содержать один или более заместителей, или
R3 и R4, связанные через атом азота, к которому присоединены R3 и R4, могут образовывать насыщенную гетероциклическую группу;
R5 представляет собой водород или C1-6 алкил, который может содержать один или более заместителей; и
n представляет собой 1 или 2;
или его соль.
2. Пиперазиновое соединение или его соль в соответствии с п.1, где
R1 представляет собой метил или этил;
R2 представляет собой гидрокси, C1-6 алкил, который может иметь одну или более насыщенных или ненасыщенных гетероциклических групп в качестве заместителей, -(C=O)-N(R3)(R4) или -(C=O)-OR5;
R3 и R4 могут быть одинаковыми или отличаться, и каждый представляет собой водород или C1-6 алкил, который может иметь одну или более насыщенных или ненасыщенных гетероциклических групп в качестве заместителей, или
R3 и R4, связанные через атом азота, к которому присоединены R3 и R4, могут образовать пирролидинил, пиперидинил, пиперазинил и морфолино;
R5 представляет собой водород, метил, этил, трет-бутил или бензил; и
n представляет собой 1 или 2.
3. Пиперазиновое соединение или его соль в соответствии с п.1, где
R1 представляет собой метил;
R2 представляет собой C1-3 алкил, который может содержать морфолино, пиразолил или триазолил в качестве заместителей, -(C=O)-N(R3)(R4) или -(C=O)-OR5; и триазолил может содержать один или два заместителя;
R3 и R4, связанные через атом азота, к которому присоединены R3 и R4, могут образовывать морфолино;
R5 представляет собой водород, метил или этил; и
n представляет собой 2.
4. Пиперазиновое соединение или его соль по п.1, где
R1 представляет собой метил;
R2 представляет собой линейный C1-3 алкил, который может содержать любой из 1,2,3-триазолила, 3,5-диметил-1,2,4-триазолила и морфолино в качестве заместителя, -(C=O)-N(R3)(R4) или -(C=O)-OR5;
R3 и R4, связанные через атом азота, к которому присоединены R3 и R4, могут образовать морфолино;
R5 представляет собой водород или этил; и
n представляет собой 2.
5. Пиперазиновое соединение или его соль в соответствии с п.1, выбранное из группы, состоящей из следующего:
N-(4-(4-гидроксипиперидин-1-ил)фенил)-4-((1-метилпиррол-2-ил)карбонил)-1-пиперазинкарбоксамид,
4-((((1-метилпиррол-2-ил)карбонил)-1-пиперазинил)карбонил)амино-4-фенилпиперидин-4-карбоновая кислота,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-морфолин-1-ил-карбонилпиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-морфолинометилпиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(3-(2-(1,2,4-триазол-1-ил)этил)пирролидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-морфолиноэтилпиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-(1-метилпиррол-2-ил)карбонил)-N-(4-(4-(2-(1,2,3-триазол-1-ил)этил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(2-(1,2,4-триазол-1-ил)этил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(2-(3,5-диметил-1,2,4-триазол-1-ил)этил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(2-(пиразол-1-ил)этил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(3-(1,2,4-триазол-1-ил)пропил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(3-(1,2,3-триазол-1-ил)пропил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-этилпиррол-2-ил)карбонил)-N-(4-(4-морфолин-1-ил-карбонилпиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-пиперидин-1-ил-карбонилпиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(4-метилпиперазин-1-ил-карбонил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид,
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(2-морфолиноэтилкарбамоил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид и
4-((1-метилпиррол-2-ил)карбонил)-N-(4-(4-(пиридин-3-илметилкарбамоил)пиперидин-1-ил)фенил)-1-пиперазинкарбоксамид.
6. Фармацевтическая композиция, проявляющая ингибирующую активность в отношении простагландин-D-синтазы, включающая эффективное количество по меньшей мере одного из соединений по пп.1-5 или его фармацевтически приемлемой соли и фармацевтически приемлемый носитель.
7. Средство для предотвращения и/или лечения заболевания, в котором участвует простагландин D2 или его метаболит, включающее эффективное количество соединения по любому из пп.1-5 или его фармацевтически приемлемой соли.
8. Средство в соответствии с п.7, где заболевание, в котором участвует простагландин D2 или его метаболит, является аллергическим заболеванием, воспалительным заболеванием или миодегенеративным заболеванием.
9. Способ предотвращения и/или лечения заболевания, в котором участвует простагландин D2 или его метаболит, где способ включает введение млекопитающему соединения по любому из пп.1-5 в количестве, эффективном для предотвращения или лечения заболевания.
10. Применение соединения по любому из пп.1-5 для получения средства для предотвращения и/или лечения заболевания, в котором участвуют простагландин D2 или его метаболит.
11. Применение соединения по любому из пп.1-5 для предотвращения и/или лечения заболевания, в котором участвуют простагландин D2 или его метаболит.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-055721 | 2009-03-09 | ||
JP2009055721 | 2009-03-09 | ||
PCT/JP2010/053760 WO2010104024A1 (ja) | 2009-03-09 | 2010-03-08 | プロスタグランジンd合成酵素を阻害するピペラジン化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011140869A true RU2011140869A (ru) | 2013-04-20 |
RU2496778C2 RU2496778C2 (ru) | 2013-10-27 |
Family
ID=42728313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011140869/04A RU2496778C2 (ru) | 2009-03-09 | 2010-03-08 | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу |
Country Status (19)
Country | Link |
---|---|
US (2) | US8865714B2 (ru) |
EP (1) | EP2407466B1 (ru) |
JP (1) | JP5111657B2 (ru) |
KR (1) | KR101421785B1 (ru) |
CN (1) | CN102341385B (ru) |
AU (1) | AU2010222122B2 (ru) |
BR (1) | BRPI1009212B8 (ru) |
CA (1) | CA2754613C (ru) |
DK (1) | DK2407466T3 (ru) |
ES (1) | ES2564454T3 (ru) |
HK (1) | HK1165419A1 (ru) |
HU (1) | HUE027702T2 (ru) |
MX (1) | MX2011009423A (ru) |
MY (1) | MY159870A (ru) |
PL (1) | PL2407466T3 (ru) |
RU (1) | RU2496778C2 (ru) |
SG (1) | SG173865A1 (ru) |
TW (1) | TWI450893B (ru) |
WO (1) | WO2010104024A1 (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2754613C (en) * | 2009-03-09 | 2016-07-12 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound capable of inhibiting prostaglandin d synthase |
SG11201501043TA (en) * | 2012-09-19 | 2015-04-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition for oral administration with improved dissolution and/or absorption |
WO2015000921A1 (en) | 2013-07-01 | 2015-01-08 | Fondazione Centro San Raffaele | Ptgds pathway activators and use in pathologies characterized by altered myelination in the cns |
TWI707851B (zh) * | 2015-09-17 | 2020-10-21 | 日商大鵬藥品工業股份有限公司 | 哌嗪化合物的新穎結晶 |
BR112018012469B1 (pt) | 2015-12-17 | 2020-11-24 | Astex Therapeutics Limited | compostos quinolina-3-carboxamidas como inibidores da h-pgds, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos. |
JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
UY37764A (es) | 2017-06-13 | 2019-01-02 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) |
MA52306A (fr) * | 2018-04-19 | 2021-02-24 | National Univ Corporation Tokyo Univ Of Agriculture And Technology | Agents préventifs et thérapeutiques de la sarcopénie |
JP2022506850A (ja) | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
CN110105286B (zh) * | 2019-05-21 | 2022-08-09 | 中国药科大学 | 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途 |
WO2021256569A1 (ja) | 2020-06-19 | 2021-12-23 | 佐藤製薬株式会社 | H-pgdsを阻害する縮環化合物 |
WO2023113023A1 (ja) * | 2021-12-17 | 2023-06-22 | 佐藤製薬株式会社 | H-pgdsを阻害するアザインドール誘導体 |
EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2108584C (en) * | 1992-10-27 | 1998-11-24 | James B. Doherty | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
JP3701878B2 (ja) * | 1995-06-21 | 2005-10-05 | 塩野義製薬株式会社 | ビシクロ環系アミノ誘導体およびそれを含有するpgd2拮抗剤 |
CA2225250C (en) | 1995-06-21 | 2005-03-22 | Shionogi & Co., Ltd. | Bicyclic amino derivatives and pgd2 antagonist containing the same |
WO1999007672A1 (en) | 1997-08-05 | 1999-02-18 | Novo Nordisk A/S | Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
DE60014603T2 (de) * | 1999-03-12 | 2006-02-16 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
MXPA05003456A (es) * | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US20090181966A1 (en) | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
US20090156611A1 (en) | 2005-11-11 | 2009-06-18 | Licentia Ltd. | Mammalian hedgehog signaling modulators |
US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
CA2754613C (en) * | 2009-03-09 | 2016-07-12 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound capable of inhibiting prostaglandin d synthase |
-
2010
- 2010-03-08 CA CA2754613A patent/CA2754613C/en active Active
- 2010-03-08 HU HUE10750777A patent/HUE027702T2/en unknown
- 2010-03-08 MX MX2011009423A patent/MX2011009423A/es active IP Right Grant
- 2010-03-08 SG SG2011061710A patent/SG173865A1/en unknown
- 2010-03-08 BR BRPI1009212A patent/BRPI1009212B8/pt active IP Right Grant
- 2010-03-08 DK DK10750777.4T patent/DK2407466T3/en active
- 2010-03-08 AU AU2010222122A patent/AU2010222122B2/en active Active
- 2010-03-08 EP EP10750777.4A patent/EP2407466B1/en active Active
- 2010-03-08 WO PCT/JP2010/053760 patent/WO2010104024A1/ja active Application Filing
- 2010-03-08 ES ES10750777.4T patent/ES2564454T3/es active Active
- 2010-03-08 JP JP2011503801A patent/JP5111657B2/ja active Active
- 2010-03-08 PL PL10750777T patent/PL2407466T3/pl unknown
- 2010-03-08 US US13/255,134 patent/US8865714B2/en active Active
- 2010-03-08 KR KR1020117023554A patent/KR101421785B1/ko active IP Right Grant
- 2010-03-08 RU RU2011140869/04A patent/RU2496778C2/ru active
- 2010-03-08 CN CN201080009882.8A patent/CN102341385B/zh active Active
- 2010-03-08 MY MYPI2011004201A patent/MY159870A/en unknown
- 2010-03-09 TW TW099106757A patent/TWI450893B/zh active
-
2012
- 2012-06-19 HK HK12106011.8A patent/HK1165419A1/xx unknown
-
2014
- 2014-01-08 US US14/150,049 patent/US9062035B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2010222122A1 (en) | 2011-09-22 |
PL2407466T3 (pl) | 2016-06-30 |
EP2407466B1 (en) | 2016-01-13 |
HK1165419A1 (en) | 2012-10-05 |
MX2011009423A (es) | 2011-09-28 |
US9062035B2 (en) | 2015-06-23 |
TWI450893B (zh) | 2014-09-01 |
EP2407466A4 (en) | 2012-09-05 |
BRPI1009212B8 (pt) | 2024-03-12 |
US20140128394A1 (en) | 2014-05-08 |
CN102341385B (zh) | 2014-01-15 |
KR101421785B1 (ko) | 2014-07-22 |
JPWO2010104024A1 (ja) | 2012-09-13 |
SG173865A1 (en) | 2011-09-29 |
DK2407466T3 (en) | 2016-03-07 |
CA2754613A1 (en) | 2010-09-16 |
CN102341385A (zh) | 2012-02-01 |
AU2010222122B2 (en) | 2013-06-27 |
RU2496778C2 (ru) | 2013-10-27 |
HUE027702T2 (en) | 2016-11-28 |
US8865714B2 (en) | 2014-10-21 |
WO2010104024A1 (ja) | 2010-09-16 |
JP5111657B2 (ja) | 2013-01-09 |
EP2407466A1 (en) | 2012-01-18 |
BRPI1009212B1 (pt) | 2024-02-20 |
BRPI1009212A2 (pt) | 2016-03-15 |
US20110319413A1 (en) | 2011-12-29 |
CA2754613C (en) | 2016-07-12 |
KR20110133040A (ko) | 2011-12-09 |
TW201100400A (en) | 2011-01-01 |
ES2564454T3 (es) | 2016-03-22 |
MY159870A (en) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2011140869A (ru) | Пиперазиновое соединение, ингибирующее простагландин-d-синтазу | |
RU2498983C2 (ru) | Соединения фениламинопиримидина и их применения | |
RU2008105304A (ru) | Соединение бензоимидазола, способное к ингибированию простагландин-d-синтетазы | |
PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
JP2016504378A5 (ru) | ||
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
RU2011127451A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА | |
RU2012144317A (ru) | Противоинфекционные соединения | |
NZ603364A (en) | Inhibitors of arginase and their therapeutic applications | |
SI2961736T1 (en) | Histone demethylase inhibitors | |
NZ593030A (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
JP2014516360A5 (ru) | ||
NZ593295A (en) | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinase inhibitor | |
TW200730501A (en) | Heterocyclic derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase I | |
AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
NZ612119A (en) | Use of sigma ligands in bone cancer pain | |
NZ627750A (en) | Carbamate compounds and of making and using same | |
NZ591427A (en) | P38 map kinase inhibitors | |
RU2013151174A (ru) | Замещенные пиримидинилпирролы, активные в качестве ингибиторов киназы | |
NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
RS52155B (en) | PYROLO (3,4-c) PIRAZOL DERIVATIVE ACTIVE AS KINASE INHIBITORS | |
NZ592297A (en) | 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents | |
RU2015101115A (ru) | Гетероароматическое циклическое производное с алкильной разветвленной цепью | |
RU2010142936A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРАЗИНА КАК ИНГИБИТОРЫ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ | |
NZ602289A (en) | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias |